RR-301

RR-301 is a preclinical-stage bispecific antibody-drug conjugate (ADC) being developed by Roadrunner Therapeutics for the treatment of refractory and drug-resistant solid tumors. As a bispecific ADC, it is engineered to recognize two different tumor-associated antigens, which potentially increases tumor selectivity and payload internalization compared to monospecific ADCs. This dual-targeting approach is intended to address tumor heterogeneity and overcome common resistance mechanisms in advanced cancers. While the specific molecular targets for RR-301 have not been disclosed, the company is advancing the program toward an anticipated first Investigational New Drug (IND) filing for its pipeline in 2027.